- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05067140
En studie av ARV-766 gett genom munnen hos män med metastaserad kastrationsresistent prostatacancer som har utvecklats med tidigare godkända systemiska terapier
En klinisk fas 1/2 öppen prövning, dosupptrappning och kohortexpansion för att utvärdera säkerheten, tolerabiliteten, farmakokinetiken och farmakodynamiken hos ARV-766 hos patienter med metastaserad kastrationsresistent prostatacancer
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
The study consists of multiple parts.
- Part A evaluates JSB462 monotherapy in a dose-escalation setting to determine safety, tolerability, dose-limiting toxicities, and the maximum tolerated dose or recommended Phase 2 dose (RP2D). Dose escalation follows an accelerated titration design transitioning to a 3+3 design.
- Part B is a randomized cohort expansion evaluating JSB462 monotherapy at selected dose levels (e.g., 100 mg or 300 mg once daily) to further assess safety and preliminary antitumor activity at the RP2D. Participants are randomized in a 1:1 ratio.
- Part C evaluates JSB462 in combination with abiraterone, administered with corticosteroid and ongoing androgen deprivation therapy. This part assesses safety, tolerability, pharmacokinetics, and defines a recommended dose for the combination regimen. An abiraterone lead-in period is implemented prior to combination treatment.
The study population includes adult males with metastatic prostate cancer. In Parts A and B, participants have metastatic castration-resistant prostate cancer (mCRPC) following prior systemic therapy. Part C includes participants with metastatic prostate cancer, including those who may be naïve to novel hormonal agents.
Primary objectives focus on safety and tolerability, including incidence of adverse events, laboratory abnormalities, and dose-limiting toxicities. In the expansion phase, antitumor activity is evaluated using prostate-specific antigen (PSA) response rates (e.g., PSA30 and PSA50).
Secondary objectives include characterization of pharmacokinetics and further assessment of antitumor activity using endpoints such as objective response rate, radiographic progression-free survival, duration of response, and time to PSA progression. Tumor assessments are performed using modified Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 for soft tissue disease and Prostate Cancer Working Group 3 (PCWG3) criteria for bone disease, with imaging conducted at regular intervals.
This study aims to characterize the clinical profile of JSB462 and explore its potential to overcome resistance mechanisms associated with androgen receptor signaling in metastatic prostate cancer.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studieorter
-
-
California
-
Duarte, California, Förenta staterna, 91010
- City of Hope National Medical
-
La Jolla, California, Förenta staterna, 92093-0658
- University of California San Diego - Moores Cancer Center
-
Santa Monica, California, Förenta staterna, 90404
- Providence Saint Johns Health Ctr
-
-
Connecticut
-
New Haven, Connecticut, Förenta staterna, 06520
- Yale Cancer Center
-
-
Florida
-
Fort Myers, Florida, Förenta staterna, 33901
- Florida Cancer Specialists
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21204
- Chesapeake Urology Associates
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Massachusetts General Hospital
-
-
Michigan
-
Detroit, Michigan, Förenta staterna, 48201
- Karmanos Cancer Institute
-
-
New York
-
Buffalo, New York, Förenta staterna, 14203
- Roswell Park Cancer Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19111
- Fox Chase Cancer Center
-
Pittsburgh, Pennsylvania, Förenta staterna, 15232
- Univ of Pittsburgh Cancer Inst
-
-
South Carolina
-
Myrtle Beach, South Carolina, Förenta staterna, 29572
- Carolina Urologic Research Center
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- SCRI Oncology Partners
-
-
Texas
-
San Antonio, Texas, Förenta staterna, 78229
- Urology San Antonio
-
-
Virginia
-
Charlottesville, Virginia, Förenta staterna, 22908
- University of Virginia Medical Center
-
Fairfax, Virginia, Förenta staterna, 22031
- Virginia Cancer Specialists
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53792-6164
- University of Wisconsin Paul P Carbone Comp Cancer Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Beskrivning
Inklusionskriterier:
Del A och B:
- Histologisk, patologisk eller cytologisk bekräftad diagnos av adenokarcinom i prostata.
- Progressiv mCRPC
- Pågående androgendeprivationsterapi (ADT) med en gonadotropinfrisättande hormonanalog eller hämmare, eller orkiektomi (kirurgisk eller medicinsk kastration).
- Eastern Cooperative Oncology Group (ECOG) prestandastatus på 0 eller 1
Del A:
• Progression på minst 2 tidigare godkända systemiska behandlingar för metastaserande prostatacancer (minst en måste vara en andra generationens androgenhämmare, t.ex. abirateron, enzalutamid, darolutamid, apalutamid).
Del B:
- Deltagare måste ha fått minst en men högst tre tidigare andra generationens anti-androgenmedel (t.ex. enzalutamid eller abirateron).
- Deltagarna får inte ha fått mer än två tidigare kemoterapikurer.
Exklusions kriterier:
Del A och B:
- Kända symtomatiska hjärnmetastaser som kräver steroider (över fysiologiska ersättningsdoser).
- Aktiv inflammatorisk gastrointestinal sjukdom, kronisk diarré, känd divertikelsjukdom eller tidigare magresektion eller knäbandskirurgi.
- Strålbehandling inom 4 veckor efter första dosen av studieläkemedlet eller tidigare bestrålning till >25 % av benmärgen.
- Mottagande av ett eller flera prövningsläkemedel inom 4 veckor före förväntad första dos
- Systemisk anti-cancerbehandling inom 2 veckor efter första dosen av studieläkemedlet (förutom medel för att bibehålla kastratstatus). För bicalutamid, mitomycin C eller nitrosoureas måste uteslutningsperioden vara 6 veckor och för abirateron 4 veckor.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part A: ARV-766 Monotherapy (Dose Escalation)
Participants with metastatic prostate cancer received escalating dose levels of ARV-766 administered orally to evaluate safety, tolerability, pharmacokinetics, and to determine the maximum tolerated dose and/or recommended Phase 2 dose.
Participants continued androgen deprivation therapy as clinically indicated.
|
Parts A and C: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment. Part B: 100mg or 300mg oral tablet(s) once daily in 28 day cycles.
Andra namn:
Ongoing androgen deprivation therapy, including luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or prior orchiectomy, is maintained per investigator choice or patient preference.
Andra namn:
|
|
Experimentell: Part B: ARV-766 Monotherapy (Dose Expansion)
Participants with metastatic castration-resistant prostate cancer received ARV-766 administered orally at selected dose levels to further evaluate antitumor activity, safety, tolerability, and pharmacokinetics.
Participants continued androgen deprivation therapy as clinically indicated.
|
Parts A and C: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment. Part B: 100mg or 300mg oral tablet(s) once daily in 28 day cycles.
Andra namn:
Ongoing androgen deprivation therapy, including luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or prior orchiectomy, is maintained per investigator choice or patient preference.
Andra namn:
|
|
Experimentell: Part C: ARV-766 + Abiraterone
Participants received ARV-766 in combination with abiraterone acetate and a corticosteroid (prednisone or prednisolone) to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of the combination regimen.
Participants continued androgen deprivation therapy as clinically indicated.
|
Parts A and C: Daily oral dosages are determined by cohort review committee after initial starting dose cohort and each subsequent cohort completes 28 days of treatment. Part B: 100mg or 300mg oral tablet(s) once daily in 28 day cycles.
Andra namn:
Ongoing androgen deprivation therapy, including luteinizing hormone-releasing hormone (LHRH) agonist/antagonist or prior orchiectomy, is maintained per investigator choice or patient preference.
Andra namn:
Abiraterone is administered orally in combination with ARV-766, typically on an empty stomach with water, in accordance with prescribing information and standard clinical practice.
Andra namn:
Prednisone or prednisolone was administered in accordance with local prescribing information during treatment with abiraterone acetate.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Part A: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of treatment
Tidsram: Up to 28 days
|
Number and proportion of participants experiencing dose-limiting toxicities during the DLT evaluation period to assess safety and determine the maximum tolerated dose (MTD) of ARV-766 and/or recommended Phase 2 dose (RP2D)
|
Up to 28 days
|
|
Part C: Incidence and severity of dose limiting toxicities (DLTs) during the first cycle of treatment
Tidsram: Up to 28 Days
|
Number and proportion of participants experiencing dose-limiting toxicities during the DLT evaluation period to determine the recommended dose of ARV-766 in combination with abiraterone
|
Up to 28 Days
|
|
Parts A and C: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: From first dose through approximately 30 days after last dose
|
Adverse events as characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), timing, seriousness, and relationship to study drug.
|
From first dose through approximately 30 days after last dose
|
|
Parts A and C: Incidence of laboratory abnormalities
Tidsram: From first dose through approximately 30 days after last dose
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), and timing.
|
From first dose through approximately 30 days after last dose
|
|
Part B: Prostate-Specific Antigen 30% Response Rate (PSA30)
Tidsram: 12 Weeks
|
Prostate Specific Antigen 30 (PSA30) Rate is defined as the proportion of participants who achieve a ≥30% decrease from baseline at any timepoint, confirmed by a second PSA measurement ≥3 weeks without any PSA progression in between
|
12 Weeks
|
|
Part B: Prostate-Specific Antigen 50% Response Rate (PSA50)
Tidsram: 12 Weeks
|
Prostate Specific Antigen 50 (PSA50) Rate is defined as the proportion of participants who achieve a ≥50% decrease from baseline at any timepoint, confirmed by a second PSA measurement ≥3 weeks without any PSA progression in between
|
12 Weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Part A: Prostate-Specific Antigen 30% Response Rate (PSA30)
Tidsram: 12 Weeks
|
Prostate Specific Antigen 30 (PSA30) Rate is defined as the proportion of participants who achieve a ≥30% decrease from baseline at any timepoint, confirmed by a second PSA measurement ≥3 weeks without any PSA progression in between
|
12 Weeks
|
|
Part A: Prostate-Specific Antigen 50% Response Rate (PSA50)
Tidsram: 12 Weeks
|
Prostate Specific Antigen 50 (PSA50) Rate is defined as the proportion of participants who achieve a ≥50% decrease from baseline at any timepoint, confirmed by a second PSA measurement ≥3 weeks without any PSA progression in between
|
12 Weeks
|
|
Part A: Objective Response Rate (ORR)
Tidsram: 12 Weeks
|
Overall Response Rate (ORR) is defined as the proportion of participants achieving a confirmed complete response (CR) or partial response (PR) per PCWG3-modified RECIST 1.1 as assessed by the investigator
|
12 Weeks
|
|
Parts A and B: Radiographic Progression-Free Survival (rPFS)
Tidsram: Baseline to radiographic progression or death, whichever occurs first, assessed up to 68 months
|
Time from first dose to radiographic disease progression per modified RECIST Version 1.1 for soft tissue lesions and PCWG3 criteria for bone lesions, or death from any cause.
|
Baseline to radiographic progression or death, whichever occurs first, assessed up to 68 months
|
|
Parts A and B: Duration of Response (DoR)
Tidsram: From first documented response to disease progression or death, whichever occurs first, assessed up to 68 months
|
Duration of Response (DOR) is defined as the time between first documented CR/PR and disease progression or death due to any cause per PCWG3-modified RECIST 1.1 as assessed by the investigator
|
From first documented response to disease progression or death, whichever occurs first, assessed up to 68 months
|
|
Parts A and B: Time to Prostate-Specific Antigen Progression
Tidsram: Baseline to prostate-specific antigen progression, assessed up to 68 months
|
Time to PSA progression is the time interval from the date of first study drug dose to the date of PSA progression.
The PSA progression date is defined as the date that a ≥25% increase and an absolute increase of ≥2 ng/mL above the nadir is documented, which is confirmed by a second consecutive value obtained 3 or more weeks later
|
Baseline to prostate-specific antigen progression, assessed up to 68 months
|
|
Part A: Area Under the plasma Concentration-Time Curve (AUC) of ARV-766
Tidsram: Cycle 1: Days 1 & 21 (0, 1, 2, 3, 4, 6, 8 and 12 hours), Day 2 (0 hour). Cycle 2 and beyond (0 hour). End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Venous whole blood samples will be collected for ARV-766 characterization.
Area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUClast), Area under the plasma concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) and Area under the plasma concentration-time curve from time zero during a dosing interval (AUCtau) will be listed and summarized using descriptive statistics.
|
Cycle 1: Days 1 & 21 (0, 1, 2, 3, 4, 6, 8 and 12 hours), Day 2 (0 hour). Cycle 2 and beyond (0 hour). End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
|
Part A: Maximum Observed Concentration (Cmax) of ARV-766
Tidsram: Cycle 1: Days 1 & 21 (0, 1, 2, 3, 4, 6, 8 and 12 hours), Day 2 (0 hour). Cycle 2 and beyond (0 hour). End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Venous whole blood samples will be collected for ARV-766 characterization.
Cmax will be listed and summarized using descriptive statistics.
|
Cycle 1: Days 1 & 21 (0, 1, 2, 3, 4, 6, 8 and 12 hours), Day 2 (0 hour). Cycle 2 and beyond (0 hour). End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
|
Part A: Time to Maximum Concentration (Tmax) of ARV-766
Tidsram: Cycle 1: Days 1 & 21 (0, 1, 2, 3, 4, 6, 8 and 12 hours), Day 2 (0 hour). Cycle 2 and beyond (0 hour). End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Venous whole blood samples will be collected for ARV-766 characterization.
Tmax will be listed and summarized using descriptive statistics.
|
Cycle 1: Days 1 & 21 (0, 1, 2, 3, 4, 6, 8 and 12 hours), Day 2 (0 hour). Cycle 2 and beyond (0 hour). End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
|
Part A: Last Measurable Concentration (Clast) of ARV-766
Tidsram: Cycle 1: Days 1 & 21 (0, 1, 2, 3, 4, 6, 8 and 12 hours), Day 2 (0 hour). Cycle 2 and beyond (0 hour). End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Venous whole blood samples will be collected for ARV-766 characterization.
Clast will be listed and summarized using descriptive statistics.
|
Cycle 1: Days 1 & 21 (0, 1, 2, 3, 4, 6, 8 and 12 hours), Day 2 (0 hour). Cycle 2 and beyond (0 hour). End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
|
Part A: Minimum Observed Concentration (Cmin) of ARV-766
Tidsram: Cycle 1: Days 1 & 21 (0, 1, 2, 3, 4, 6, 8 and 12 hours), Day 2 (0 hour). Cycle 2 and beyond (0 hour). End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Venous whole blood samples will be collected for ARV-766 characterization.
Cmin will be listed and summarized using descriptive statistics.
|
Cycle 1: Days 1 & 21 (0, 1, 2, 3, 4, 6, 8 and 12 hours), Day 2 (0 hour). Cycle 2 and beyond (0 hour). End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
|
Part A: Apparent total body clearance (CL/F) of ARV-766
Tidsram: Cycle 1: Days 1 & 21 (0, 1, 2, 3, 4, 6, 8 and 12 hours), Day 2 (0 hour). Cycle 2 and beyond (0 hour). End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Venous whole blood samples will be collected for ARV-766 characterization.
CL/F will be listed and summarized using descriptive statistics.
|
Cycle 1: Days 1 & 21 (0, 1, 2, 3, 4, 6, 8 and 12 hours), Day 2 (0 hour). Cycle 2 and beyond (0 hour). End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
|
Part A: Apparent Volume of Distribution (Vd/F) of ARV-766
Tidsram: Cycle 1: Days 1 & 21 (0, 1, 2, 3, 4, 6, 8 and 12 hours), Day 2 (0 hour). Cycle 2 and beyond (0 hour). End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Venous whole blood samples will be collected for ARV-766 characterization.
Vd/F will be listed and summarized using descriptive statistics.
|
Cycle 1: Days 1 & 21 (0, 1, 2, 3, 4, 6, 8 and 12 hours), Day 2 (0 hour). Cycle 2 and beyond (0 hour). End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
|
Part B: Incidence rate of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: From first dose through approximately 30 days after last dose
|
Adverse events as characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), timing, seriousness, and relationship to study drug.
|
From first dose through approximately 30 days after last dose
|
|
Part B: Incidence of laboratory abnormalities
Tidsram: From first dose through approximately 30 days after last dose
|
Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v 5.0), and timing.
|
From first dose through approximately 30 days after last dose
|
|
Part C: Area Under the plasma Concentration-Time Curve (AUC) of Abiraterone/ARV-766
Tidsram: Cycle 1 Days -8, -1, 1, 21, and 28; Cycle 2 Day 28; and Cycle ≥3 Day 28 (odd cycles only), with intensive post-dose PK on Days -1, 1, and 21; End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Venous whole blood samples will be collected for Abiraterone/ARV-766 characterization.
Area under the plasma concentration-time curve from time zero to the time of last quantifiable concentration (AUClast), Area under the plasma concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUCinf) and Area under the plasma concentration-time curve from time zero during a dosing interval (AUCtau) will be listed and summarized using descriptive statistics.
|
Cycle 1 Days -8, -1, 1, 21, and 28; Cycle 2 Day 28; and Cycle ≥3 Day 28 (odd cycles only), with intensive post-dose PK on Days -1, 1, and 21; End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
|
Part C: Maximum Observed Concentration (Cmax) of ARV-766
Tidsram: Cycle 1 Days -8, -1, 1, 21, and 28; Cycle 2 Day 28; and Cycle ≥3 Day 28 (odd cycles only), with intensive post-dose PK on Days -1, 1, and 21; End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Venous whole blood samples will be collected for ARV-766 characterization.
Cmax will be listed and summarized using descriptive statistics.
|
Cycle 1 Days -8, -1, 1, 21, and 28; Cycle 2 Day 28; and Cycle ≥3 Day 28 (odd cycles only), with intensive post-dose PK on Days -1, 1, and 21; End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
|
Part C: Time to Maximum Concentration (Tmax) of ARV-766
Tidsram: Cycle 1 Days -8, -1, 1, 21, and 28; Cycle 2 Day 28; and Cycle ≥3 Day 28 (odd cycles only), with intensive post-dose PK on Days -1, 1, and 21; End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Venous whole blood samples will be collected for ARV-766 characterization.
Tmax will be listed and summarized using descriptive statistics.
|
Cycle 1 Days -8, -1, 1, 21, and 28; Cycle 2 Day 28; and Cycle ≥3 Day 28 (odd cycles only), with intensive post-dose PK on Days -1, 1, and 21; End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
|
Part C: Last Measurable Concentration (Clast) of ARV-766
Tidsram: Cycle 1 Days -8, -1, 1, 21, and 28; Cycle 2 Day 28; and Cycle ≥3 Day 28 (odd cycles only), with intensive post-dose PK on Days -1, 1, and 21; End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Venous whole blood samples will be collected for ARV-766 characterization.
Clast will be listed and summarized using descriptive statistics.
|
Cycle 1 Days -8, -1, 1, 21, and 28; Cycle 2 Day 28; and Cycle ≥3 Day 28 (odd cycles only), with intensive post-dose PK on Days -1, 1, and 21; End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
|
Part C: Minimum Observed Concentration (Cmin) of ARV-766
Tidsram: Cycle 1 Days -8, -1, 1, 21, and 28; Cycle 2 Day 28; and Cycle ≥3 Day 28 (odd cycles only), with intensive post-dose PK on Days -1, 1, and 21; End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Venous whole blood samples will be collected for ARV-766 characterization.
Cmin will be listed and summarized using descriptive statistics.
|
Cycle 1 Days -8, -1, 1, 21, and 28; Cycle 2 Day 28; and Cycle ≥3 Day 28 (odd cycles only), with intensive post-dose PK on Days -1, 1, and 21; End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
|
Part C: Apparent total body clearance (CL/F) of ARV-766
Tidsram: Cycle 1 Days -8, -1, 1, 21, and 28; Cycle 2 Day 28; and Cycle ≥3 Day 28 (odd cycles only), with intensive post-dose PK on Days -1, 1, and 21; End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Venous whole blood samples will be collected for ARV-766 characterization.
CL/F will be listed and summarized using descriptive statistics.
|
Cycle 1 Days -8, -1, 1, 21, and 28; Cycle 2 Day 28; and Cycle ≥3 Day 28 (odd cycles only), with intensive post-dose PK on Days -1, 1, and 21; End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
|
Part C: Apparent Volume of Distribution (Vd/F) of ARV-766
Tidsram: Cycle 1 Days -8, -1, 1, 21, and 28; Cycle 2 Day 28; and Cycle ≥3 Day 28 (odd cycles only), with intensive post-dose PK on Days -1, 1, and 21; End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Venous whole blood samples will be collected for ARV-766 characterization.
Vd/F will be listed and summarized using descriptive statistics.
|
Cycle 1 Days -8, -1, 1, 21, and 28; Cycle 2 Day 28; and Cycle ≥3 Day 28 (odd cycles only), with intensive post-dose PK on Days -1, 1, and 21; End of Treatment Visit (EOT): within 4 weeks from the last dose of ARV-766. 1 cycle = 28 days.
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Urogenitala sjukdomar
- Genitala sjukdomar
- Neoplasmer efter plats
- Neoplasmer
- Genitala sjukdomar, manliga
- Prostatasjukdomar
- Manliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar
- Kvinnliga urogenitala sjukdomar och graviditetskomplikationer
- Prostatiska neoplasmer
- Urogenitala neoplasmer
- Genitala neoplasmer, manliga
- Läkemedels fysiologiska effekter
- Hormoner
- Hormoner, hormonsubstitut och hormonantagonister
- Hormonantagonister
- Hypofyshormonfrisättande hormoner
- Hypotalamiska hormoner
- Peptidhormoner
- Neuropeptider
- Peptider
- Aminosyror, peptider och proteiner
- Oligopeptider
- Nervvävnadsproteiner
- Proteiner
- Farmakologiska åtgärder
- Kemiska åtgärder och användningar
- Polycykliska föreningar
- Graviditet
- Graviditet
- Steroider
- Fusion-ringföreningar
- Graviditet
- Gravidioder
- Androstenes
- Androstaner
- Abirateronacetat
- Prednison
- Prednisolon
- Androgenantagonister
- Gonadotropinfrisättande hormon
- abirateron
- Binjurhormoner
Andra studie-ID-nummer
- CJSB462A12101
- ARV-766-mCRPC-101 (Annan identifierare: Arvinas Inc.)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .